Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabela Lens

Showing results (121-130 of 162) with videos related to

Pageof 17
Sort By:
Gastroenterologia Y Hepatologia|October 18, 2022
Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extractionJavier Crespo, Joaquín Cabezas, Antonio Aguilera, et al.
The Lancet. Gastroenterology & Hepatology|March 5, 2022
The present and future of gastroenterology and hepatology: an international SWOT analysis (the GASTROSWOT project)Enrique de-Madaria, José J Mira, Irene Carrillo, et al.
Journal of Hepatology|December 2, 2021
Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodulesMarco Sanduzzi-Zamparelli, Zoe Mariño, Sabela Lens, et al.
Annals of Hepatology|May 29, 2015
High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in SpainJavier Crespo, Moisés Diago, Joaquín Cabezas, et al.
Gastroenterologia Y Hepatologia|February 2, 2023
mTOR inhibitors a potential predisposing factor for chronic hepatitis E: Results from the prospective collaborative CHES study (Chronic Hepatitis EScreening in patients with immune impairment and increased transaminases levels)Mar Riveiro-Barciela, Luisa Roade, Joan Martínez-Camprecios, et al.
Gastroenterology|July 1, 2018
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and CirrhosisRafael Esteban, Juan A Pineda, Jose Luis Calleja, et al.
Digestive Diseases and Sciences|January 13, 2017
Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular CarcinomaMar Riveiro-Barciela, David Tabernero, José L Calleja, et al.
BMC Gastroenterology|February 3, 2025
Liver cancer risk and changes in lifestyle habits after successful hepatitis C virus therapy post-DAA HCV therapy: lifestyle changes and liver cancer riskNúria Granel, Gemma Iserte, Concepció Bartres, et al.
Journal of Hepatology|December 15, 2020
Corrigendum to "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules" [J Hepatol (2019) 874-884]Zoe Mariño, Anna Darnell, Sabela Lens, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 31, 2018
Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohortMarc Puigvehí, Beatriz De Cuenca, Ana Viu, et al.
Pageof 17

Showing results (121-130 of 162) with videos related to

Sort By:
Pageof 17
Gastroenterologia Y Hepatologia|October 18, 2022
Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extractionJavier Crespo, Joaquín Cabezas, Antonio Aguilera, et al.
The Lancet. Gastroenterology & Hepatology|March 5, 2022
The present and future of gastroenterology and hepatology: an international SWOT analysis (the GASTROSWOT project)Enrique de-Madaria, José J Mira, Irene Carrillo, et al.
Journal of Hepatology|December 2, 2021
Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodulesMarco Sanduzzi-Zamparelli, Zoe Mariño, Sabela Lens, et al.
Annals of Hepatology|May 29, 2015
High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in SpainJavier Crespo, Moisés Diago, Joaquín Cabezas, et al.
Gastroenterologia Y Hepatologia|February 2, 2023
mTOR inhibitors a potential predisposing factor for chronic hepatitis E: Results from the prospective collaborative CHES study (Chronic Hepatitis EScreening in patients with immune impairment and increased transaminases levels)Mar Riveiro-Barciela, Luisa Roade, Joan Martínez-Camprecios, et al.
Gastroenterology|July 1, 2018
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and CirrhosisRafael Esteban, Juan A Pineda, Jose Luis Calleja, et al.
Digestive Diseases and Sciences|January 13, 2017
Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular CarcinomaMar Riveiro-Barciela, David Tabernero, José L Calleja, et al.
BMC Gastroenterology|February 3, 2025
Liver cancer risk and changes in lifestyle habits after successful hepatitis C virus therapy post-DAA HCV therapy: lifestyle changes and liver cancer riskNúria Granel, Gemma Iserte, Concepció Bartres, et al.
Journal of Hepatology|December 15, 2020
Corrigendum to "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules" [J Hepatol (2019) 874-884]Zoe Mariño, Anna Darnell, Sabela Lens, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 31, 2018
Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohortMarc Puigvehí, Beatriz De Cuenca, Ana Viu, et al.
Pageof 17